SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SCHOTT Pharma AG & Co KgaA
Free Cash Flow
SCHOTT Pharma AG & Co KgaA
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
|
Free Cash Flow
€35.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
E
|
Evotec SE
XETRA:EVT
|
Free Cash Flow
-€91.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Gerresheimer AG
XETRA:GXI
|
Free Cash Flow
-€86.7m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
SCHOTT Pharma AG & Co KgaA
Glance View
SCHOTT Pharma AG & Co KgaA, carved from the renowned SCHOTT AG, stands as a beacon in the pharmaceutical packaging industry. With roots deeply embedded in scientific glass manufacturing, SCHOTT Pharma specializes in providing sophisticated solutions for the containment and delivery of medicines. Their core expertise revolves around the development and production of high-quality glass and polymer products, including pre-fillable syringes, vials, and cartridges. These products are meticulously crafted to meet the stringent safety and quality demands of the healthcare sector, ensuring optimal preservation and delivery of pharmaceutical substances. The company leverages its profound understanding of material science, coupled with a focus on innovation, to offer tailored solutions to pharmaceutical companies across the globe. SCHOTT Pharma's business model thrives on collaboration and partnership with its clients, ensuring their specific needs are met with precision. The firm earns its revenue by forging long-term relationships with leading pharmaceutical players, supplying them with specialized containers designed to enhance drug stability and extend shelf life. This relationship is symbiotic, as SCHOTT Pharma not only provides the physical packaging but also lends its expertise in regulatory compliance and product testing, thereby positioning itself as a crucial contributor to its clients' overall success. By investing deeply in research and development, SCHOTT Pharma continues to innovate, maintaining its competitive edge and ensuring consistent demand for its high-performance pharmaceutical packaging solutions.
See Also
What is SCHOTT Pharma AG & Co KgaA's Free Cash Flow?
Free Cash Flow
35.2m
EUR
Based on the financial report for Sep 30, 2025, SCHOTT Pharma AG & Co KgaA's Free Cash Flow amounts to 35.2m EUR.
What is SCHOTT Pharma AG & Co KgaA's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
13%
Over the last year, the Free Cash Flow growth was -56%. The average annual Free Cash Flow growth rates for SCHOTT Pharma AG & Co KgaA have been 6% over the past three years , 13% over the past five years .